Home » Stocks » SPRB

Spruce Biosciences, Inc. (SPRB)

Stock Price: $15.41 USD -0.17 (-1.09%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 362.81M
Revenue (ttm) n/a
Net Income (ttm) -29.54M
Shares Out 23.30M
EPS (ttm) -4.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $15.41
Previous Close $15.58
Change ($) -0.17
Change (%) -1.09%
Day's Open 15.57
Day's Range 15.28 - 16.00
Day's Volume 91,450
52-Week Range 14.18 - 35.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates

1 month ago - Business Wire

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #ENDO2021--Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society's 2021 Annual Mtg

1 month ago - Business Wire

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society's 2021 Annual Meeting

2 months ago - Business Wire

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences to Participate in Upcoming Investor Conferences

2 months ago - Business Wire

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021

4 months ago - Business Wire

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes

4 months ago - Business Wire

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

5 months ago - Business Wire

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference

6 months ago - Business Wire

After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular way US IPOs ...

Other stocks mentioned: AYLA, FUBO, GAN, INTZ, KC, KRON, STTK
6 months ago - Seeking Alpha

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

6 months ago - Business Wire

U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week

Other stocks mentioned: FUBO, INTZ, KRON, MAACU, MUDSU, NGACU, STTK
6 months ago - Seeking Alpha

Shares of Spruce Biosciences Inc. rallied in their public debut, as they opened 21% above the initial public offering price. The stock's first trade was at $18.14 at 11:37 a.m.

6 months ago - Market Watch

Spruce Biosciences Inc. said Friday that its initial public offering, which was upsized by 20%, priced at $15 a share, as the California-based biopharmaceutical company developing treatments for endocri...

6 months ago - Market Watch

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Announces Pricing of Upsized Initial Public Offering

6 months ago - Business Wire

About SPRB

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b c... [Read more...]

Industry
Biotechnology
IPO Date
Oct 9, 2020
Stock Exchange
NASDAQ
Ticker Symbol
SPRB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SPRB stock is "Buy." The 12-month stock price forecast is 33.25, which is an increase of 115.77% from the latest price.

Price Target
$33.25
(115.77% upside)
Analyst Consensus: Buy